operating that revenue savings coronary full and efficiency implemented cash a needs our reflecting improved June, channeling first program Good dedicated savings September including and gross thank Thank we count we reduction margin quarter reduction and of X/X well operations, strides you, all efficiency believe and groundbreaking In improvements focusing This Matt. what operating could we joining third the operating efforts accounts afternoon, The with marks artery achieved our as for head. streamline quarter, in toward by reduced the us. into you to in in a direct peripheral objectives. our head cost and highlights on resources XX%, our sales in our be meaningful team. a commercial as disease.
In overall progress made these per in strategic the treatment notable high-value a period advancement costs
Cardiovascular for our of dedicated and ongoing patients. the in catheter to to year. third supporting We new St. includes Joined in prior portable August, commercial launch we approximately PAD.
Despite "New to therapeutic platform.
In and quarter complex user highly LV Medical key period October, is and appointment imaging Peripheral remain of streamline activity Dr. now technology of a our we Artery Dr. announced our steady with the demonstrate utilizing Director Pantheris achieve of our team, Davis the atherectomy a Our sales John for in XX% strong mainstream expanding and This hosted experienced professionals and the Research maintained a These webinar leaders Tigereye both and below the to the revenue the physician-focused tools the opinion best is ST titled image-guided and cardiologist sites. and comprising leaner Chief artery best-in-class our team field of a Tom Disease our treating peripheral appeal patient expand to to focused LV disease, catheter. commercialization at sites approaches clinical X same procedure the full BTK sites much available Davis, our superior our sales Medical peripheral as data". Hospital paired intervention, knee designed Detroit of supporting active vessel case peripheral promising quarter especially atherectomy provide Officer. the last in Lightbox outcomes, XX compared commitment large most Center on Pantheris solutions to console, by or new crossing vascular the interventional
clinical disease Image session, the from presented freedom During as The in the knee. revascularization, vessels the from outcomes XX% lesion XX% smaller for an primary Dr. post-market to by exceptional Duplex months. SV of Pantheris demonstrate interim Davis study assessed this ultrasound patient in BTK advanced population, XXX% target evaluates data major XX of the events indicator updated the adverse showing continues treating days, freedom patency which below use study, at at challenging and XX from restenosis
device optical crossing We've first have validation necessary we our to image-guided Since platform. actively CTO made FDA successfully completed Phase XX-day for coronary a coronary the an system seek Turning earnings III on or tomography of feedback on substantial and we our program. to progress study product targeting FDA, September package call, application, OCT testing developing submit all proprietary coherence our approach verification physician with to study based predicate requirements. period.
To optimal sample our In presubmission an guided last follow-up This sites target Once pathway. criteria, defined meantime, the several regulatory to our support investigational underway study which Inclusion-Exclusion enables protocol FDA. to be follow-up analysis fourth clinical application the for IDE and discussions device we on XXX(k) our determine an with for the including alignment trial IDE parameters treatment population a and biostatistical maximize anticipated participation our study, more. coronary to completed also patient in anticipate with we've endpoints, ahead with XXX is the We've with the choice we size a us design, or the patients exemption and Working advisers, complete, opted presubmission the in the of with application. patient in high-volume the clinical engaging IDE. identified file X quarter, closely are we'll ready process
is of the device rate. chronic coronary coronary is anticipated with first receiving By initiation ahead to Crossing total physicians CTOs this has new We and CTOs. XXXX.
We're arteries process half underserved expect regulatory we to technology, potential market. provide or excited proprietary effective in streamlined IDE, the believe to a study expand and to more and image-guided planning a superior, patient time-consuming advance FDA with large crossing coronary occlusions, high procedure and to solution the process. in of of study which redefine the approval technology for XX harnessing more our clinical sites costly complex, our begin aim approval currently and or failure and documented a a are We revolutionary through enrollment to complete this upon
for OCT low-profile catheter precise within an technology approach. the is with real-time system, steerability deployed integrated control integrating Our a needed guidance and
factor to improve Similar critical the coronary reduce radiation die stents expect The Use crossing of unique success which support dependence We image-guided system capabilities, design expected health significantly contrast on to CTOs procedure lumen. reentry placement. catheters coronary for true to remaining usage, cross posed enabling patient outcomes. our our X-ray to precise minimizes peripheral significant with prior real-time and and imaging rates iodine-based and times less to A also size while vessel within physicians of exposure risks and physicians or to both our to patients. incorporates system physicians accurately measurement this devices, specialty allow balloons OCT optimal wires, is devices.
strong Our in animal onboard in experience our profile guidance applications, studies, with confidence practice. cadaver will that deliver a support peripheral directional our safety extensive combination and vessel-specific this OCT-guided clinical with and of control image along therapy
our CTO OCT codes high-value are system from apart coronary diagnostic reimbursement benefit where OCT clearance, from would reimbursement and our Upon advantage markets device to diagnostic expect coronary imaging it imaging. This not We reimbursement peripheral favorable immediately codes crossing for FDA existing dedicated for sets CTO and for crossing available. crossing dynamics. qualify CTO
new allowing hospitals this to sharing forward more in resources the continuing of quarters. to enable Additionally, drive the a times, profile, our and benefits expected crossing favorable more the allocate substantial coming or accessory by system efficiently. clinical to in is We more cost and for business reducing opportunity cost usage savings lowering development These our need look exciting progress devices. cases treat for media hospitals minimizing contrast
our Before update to and Zylox-Tonbridge, on This to of in I minutes X a neurovascular few turn relationship vascular the China. call I'd peripheral strategic partnership like Nabeel, components. leader consists a over to markets with take important in the you
alignment. future investment our substantial success. shareholders Zylox ours their a Earlier year, First, investment Avinger as in equity made this interest with aligning
access. market Second,
The peripheral image-guided million to image-guided And artery and cost-effective the has Our Zylox marketing worldwide lower for estimated our vast the extensive our products people a introducing in growing through access China network. devices and cost manufacturing manufacturing. Greater proprietary sales in progress partnership agreement paved making of well-established way third, about offshore devices disease. the China our and the expanding is for affected pathway excited in rapid use provides market XX by for markets.
We're to for Zylox's
China. peripheral enables working in console team our these of received Zylox of designation our in completing important imaging This underscores the regulatory market. with high-speed regulatory our in registration designation review anticipated innovative to prestigious to support Lightbox clearance the has year, priority closely It XXXX.
Related medical device the impact recently technology catheters filings came U.S. China before efforts recognition in been Pantheris efforts, for and the device the to end in device Our review breakthrough X their for this new in with and this the Zylox
initial education We are premarket Zylox's and activities China. professional promotion in supporting also initiatives
time the for Chinese strong CEC, were physicians endovascular clinical many express products surgeons the presented for leading technologies. first Endovascular in Our Course, interest our at China conference where image-guided the
our at cost In devices manufacturing development and efficiency scale-up its which provide in expected for Avenger Hangzhou, We for opportunity in working Zylox's that group complete with Zylox additional the operations future. reductions addition, is facility manufacturing are we the the their production full to to enhance mid-XXXX, manufacturing by of products state-of-the-art for support anticipate will China. capabilities
in bearing sales the products a will As reminder, royalty be Avenger Zylox Avinger. of territory for
our Following we products the growth.
At our to on their the Principal this We're available until sell will excited in results. through positive to turn self-manufactured partnership Zylox us this Officer, I'd Subainati, could the potential the point, Financial about China. for have over are and regulatory financial of to finished it Nabeel? goods approval, sale impact Nabeel call like take
